Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.4000 (-1.55%) ($11.2700 - $11.4000) on Sat. Apr. 15, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.16% (three month average) | RSI | 59 | Latest Price | $11.4000(-1.55%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.4% a day on average for past five trading days. | Weekly Trend | FOLD advances 0.9% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting FOLD price | FOLD will decline at least -1.08% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.08% (StdDev 2.16%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $11.27(1.15%) | 10 Day Moving Average | $11.18(1.97%) | 20 Day Moving Average | $11.18(1.97%) | To recent high | -16.5% | To recent low | 4.3% | Market Cap | $N/A | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |